Vertex Pharmaceuticals, Inc. (VRTX) Misses Q2 EPS by 13c; Revises Revenues
Tweet
Share
E-mailGet Alerts VRTX Hot Sheet
Price: $466.79 +3.36%
EPS Growth %: +4.4%
Financial Fact:
Royalty expenses: 855K
Today's EPS Names:
OCCI, MAYS, CRMT, More
EPS Growth %: +4.4%
Financial Fact:
Royalty expenses: 855K
Today's EPS Names:
OCCI, MAYS, CRMT, More
Join SI Premium – FREE
Vertex Pharmaceuticals, Inc. (NASDAQ: VRTX) reported Q2 EPS of $0.46, $0.13 worse than the analyst estimate of $0.59. Revenue for the quarter came in at $418.3 million versus the consensus estimate of $472.16 million.
Vertex today revised guidance for full-year 2012 INCIVEK net revenues. The company expects full-year 2012 INCIVEK net revenues to be in the range of $1.1 billion to $1.25 billion. The revised guidance reflects the recent downward trend in the number of patients initiating treatment within the hepatitis C market.
For earnings history and earnings-related data on Vertex Pharmaceuticals, Inc. (VRTX) click here.
Vertex today revised guidance for full-year 2012 INCIVEK net revenues. The company expects full-year 2012 INCIVEK net revenues to be in the range of $1.1 billion to $1.25 billion. The revised guidance reflects the recent downward trend in the number of patients initiating treatment within the hepatitis C market.
For earnings history and earnings-related data on Vertex Pharmaceuticals, Inc. (VRTX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Stifel Reiterates Buy Rating on FedEx (FDX) Ahead of Q4 Earnings
- Credo Technology pops 3.5% as Evercore initiates with monster $325 price target
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
